Get notified when PALX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The auditor's report and management's liquidity discussion raise substantial doubt about the company's ability to continue as a going concern.
- No Revenue (new) — The company has generated no revenue from commercial sales to date, indicating an early-stage business with high uncertainty.
- Related-party Transactions (new) — The company issued restricted stock awards to relatives of the CEO and a director for consulting and advisory services.
Palomino Laboratories registers resale of 16.1M shares at $1.50; company gets no proceeds, faces going-concern doubt
Filed February 12, 2026 · ~2 min read
Key Changes
-
high
Selling stockholders may resell up to 16,083,036 shares at a fixed $1.50 per share; Palomino receives no proceeds from the sale.
The Offering verify on EDGAR → -
high
The company reported a GAAP net loss of $2.4M for the nine months ended September 30, 2025, and has an accumulated deficit of $2.4M.
Business view on EDGAR → -
high
Auditor KNAV CPA LLP expressed substantial doubt about Palomino's ability to continue as a going concern due to recurring losses and accumulated deficit.
Risk Factors verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (WS 10-Q) is open in full — no account needed.
Partner
Trade PALX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify